From the Update: Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.

Comment: The sentence above and inclusion of news regarding an ongoing study of an additional class of virus, bunyaviruses, should be recognized as excellent news. As I read it, GMU has studied and collected data on Corona and Alphaviruses. The result of those studies comprise the finding to be presented at the annual American Society for Virology in July. GMU, having collected sufficient positive data on Corona and Alphavirus and has begun to collect positive efficacy data on to a new class of virus, bunyaviruses.

Brilacidin, a broad-spectrum antiviral is poised to rock the world.